Connect with us

Hi, what are you looking for?

Jewish Business News


Teva Offers $114 Million For Biotechnology company NuPathe

In a notice to the SEC, biotech company NuPathe said that Teva is offering $3.65 per share, compared with yesterday’s closing price of $3.23.
NuPathe migraine patch 2-304

The NuPathe migraine patch is worn on the arm or thigh

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) may be again acquiring companies. A few hours after “Reuters” reported that Teva was interested in acquiring a Korean company, a US company announced that it has received an unsolicited acquisition offer from Teva. NuPathe Inc.(Nasdaq: PATH), has a market cap of $100 million; its share price jumped 32% to $4.29 in premarket trading today. In a notice to the US Securities and Exchange Commission (SEC), NuPathe said that Teva is offering $3.65 per share, compared with yesterday’s closing price of $3.23.

NuPathe is a biotechnology company that is developing treatment for neurological disorders, including migraines, Parkinson’s disease, and schizophrenia. The company says on its website that it is seeking partners for the commercialization of its migraine treatment.


In the notice to the SEC, NuPathe said that Teva SVP and Head of Global Business Development sent an e-mail to CEO Armando Anido with an acquisition offer and draft contract. “Teva and the company had previously been in negotiations with respect to a co-promotional partnership, ” it added.

“The Wall Street Journal” says that Teva’s $114 million offer for NuPathe tops the pending deal with Endo Health Solutions Inc. (Nasdaq: ENDP). Teva is also offering up to $3.15 per share premium to Tuesday’s close. Teva also is offering up to an additional $3.15 a share if NuPathe’s Zecuity migraine treatment meets certain milestones

Published by 

1 Comment

1 Comment

  1. Pingback: J. Lewis Research, Inc. – Drug Companies Developing New Drug Delivery Methods

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...


The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

cialis cialis satış